These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33258003)

  • 1. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study.
    Pappas DA; Brittle C; Mossell JE; Withers JB; Lim-Harashima J; Kremer JM
    Rheumatol Int; 2021 Mar; 41(3):585-593. PubMed ID: 33258003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
    Cohen S; Wells AF; Curtis JR; Dhar R; Mellors T; Zhang L; Withers JB; Jones A; Ghiassian SD; Wang M; Connolly-Strong E; Rapisardo S; Gatalica Z; Pappas DA; Kremer JM; Saleh A; Akmaev VR
    Rheumatol Ther; 2021 Sep; 8(3):1159-1176. PubMed ID: 34148193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.
    Kamal KM; Madhavan SS; Hornsby JA; Miller LA; Kavookjian J; Scott V
    Joint Bone Spine; 2006 Dec; 73(6):718-24. PubMed ID: 16997599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis.
    Díaz-Torné C; Urruticoechea-Arana A; Ivorra-Cortés J; Díaz S; Dilla T; Sacristán JA; Inciarte-Mundo J; Comellas M; Prades M; Lizán L
    Adv Ther; 2020 Apr; 37(4):1479-1495. PubMed ID: 32088860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
    Endo Y; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Immunol Med; 2020 Sep; 43(3):115-120. PubMed ID: 32393150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis.
    Bergman MJ; Kivitz AJ; Pappas DA; Kremer JM; Zhang L; Jeter A; Withers JB
    Rheumatol Ther; 2020 Dec; 7(4):775-792. PubMed ID: 32797404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies.
    Karpes Matusevich AR; Duan Z; Zhao H; Lal LS; Chan W; Suarez-Almazor ME; Giordano SH; Swint JM; Lopez-Olivo MA
    Arthritis Care Res (Hoboken); 2021 Oct; 73(10):1461-1469. PubMed ID: 32558339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.
    Strand V; Cohen SB; Curtis JR; Zhang L; Kivitz AJ; Levin RW; Mathis A; Connolly-Strong E; Withers JB
    Expert Rev Mol Diagn; 2022 Jan; 22(1):101-109. PubMed ID: 34937469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
    Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
    Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.
    van Hulst LT; Kievit W; van Bommel R; van Riel PL; Fraenkel L
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1407-14. PubMed ID: 21748861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
    Jung SM; Kwok SK; Ju JH; Park YB; Park SH
    Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
    Naniwa T; Iwagaitsu S; Kajiura M
    Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
    Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
    Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
    Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
    Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of methotrexate and TNF inhibitors in patients with rheumatoid arthritis-associated interstitial lung disease: a survey of rheumatologists.
    Park E; Iqbal R; Giles JT; Bernstein EJ
    Clin Rheumatol; 2024 Sep; 43(9):3029-3032. PubMed ID: 39083189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.